<DOC>
	<DOCNO>NCT02698189</DOCNO>
	<brief_summary>This study determine recommend dose MK-8628 study participant acute myeloid leukemia ( AML ) include AML de novo AML secondary myelodysplastic syndrome ( MDS ) participant diffuse large B cell lymphoma ( DLBCL ) . The recommend dose establish evaluate dose limit toxicity ( DLT ) , safety , tolerability , early efficacy signal .</brief_summary>
	<brief_title>A Dose Exploration Study With MK-8628 Participants With Selected Hematologic Malignancies ( MK-8628-005 )</brief_title>
	<detailed_description />
	<criteria>Diagnosis AML ( AML de novo postMDS ) DLBCL AML participant must follow malignancy criterion : measurable evaluable disease per tumor response criterion ; ≥ 5 % bone marrow blast without alternate causality ; &gt; 90 day since allogeneic stem cell transplantation relapse participant relapse transplant AML participant Philadelphia chromosome positive must receive ≥ 2 line therapy , include 2 bcrabl tyrosinekinase ( TK ) inhibitor ( among imatinib , nilotinib dasatinib ) , 1 line include 1 TK inhibitor relapse/refractoriness associate detection resistance mutation inhibitor AML participant &lt; 60 year old must second relapse relapse allogeneic stem cell transplantation regardless number relapse AML participant ≥ 60 year old first relapse diseasefree interval &lt; 12 month , relapse . First relapse also applicable AML postMDS patient receive prior treatment MDS , receive prior treatment AML . DLBCL participant must follow malignancy criterion : measurable evaluable disease per tumor response criterion ≥ 1 tumor mass ≥ 15 mm ( long axis lymph node ) ≥ 10 mm ( short axis lymph node extra nodal lesion ) spiral CT scan ; fail 2 standard line therapy ( least one contain antiCD20 monoclonal antibody ) , treatment contraindicate . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤1 An interval ≥3 week since chemotherapy ( ≥ 6 week nitrosoureas mitomycin C ) , immunotherapy , hormone therapy anticancer therapy surgical intervention resection , ≥3 halflives monoclonal antibody , ≥ 5 halflives noncytotoxic agent ( whichever longer ) Female participant must pregnant ( negative urine serum human chorionic gonadotropin test within 72 hour study start ) Female male participant reproductive potential must agree use adequate contraception start first dose trial treatment 90 day last dose study medication Known primary central nervous system ( CNS ) malignancy symptomatic untreated CNS metastases History prior concomitant malignancy within 3 year study start Has serious illness medical condition , active infection , unresolved bowel obstruction , psychiatric disorder , cerebrovascular accident within 1 year study start Known history human immunodeficiency virus ( HIV ) and/or active Hepatitis B C infection Has one follow cardiacrelated condition : Congestive heart failure ; angina pectoris ; myocardial infarction ( within 1 year study start ) ; uncontrolled hypertension ; uncontrolled arrhythmia Is receive concomitant anticancer treatment Has receive high dose chemotherapy follow autologous stem cell transplantation le 90 day prior first dose study treatment Is receive concomitant therapy strong CYP3A4 CYP2A6 inhibitor inducer Is pregnant breastfeed Participation clinical trial involve investigational drug within 30 day study start Known additional malignancy progress require active treatment Has previously treat Bromodomain ExtraTerminal ( BET ) inhibitor Has acute promyelocytic leukemia , clinically uncontrolled disseminate intravascular coagulation , peripheral cytopenia Has chronic graft versus host disease ( GVHD ) immunosuppressive therapy control GVHD Has uncontrolled diseaserelated metabolic disorder Unable swallow oral medication , gastrointestinal condition deem jeopardize intestinal absorption .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>